Abstract:To turn a disease from highly fatal to highly curable is extremely difficult, especially when the disease is a type of cancer. However, we can gain some insight into how this can be done by looking back over the 50-year history of taming acute promyelocytic leukaemia (APL). APL is the M3 type of acute myeloid leukaemia characterized by an accumulation of abnormal promyelocytes in bone marrow, a severe bleeding tendency and the presence of the chromosomal translocation t(15;17) or variants. APL was considered the most fatal type of acute leukaemia five decades ago and the treatment of APL was a nightmare for physicians. Great efforts have been made by scientists worldwide to conquer this disease. The first use of chemotherapy (CT) was unsuccessful due to lack of supportive care and cytotoxic-agent-related exacerbated coagulopathy. The first breakthrough came from the use of anthracyclines which improved the complete remission (CR) rate, though the 5-year overall survival could only be attained in a small proportion of patients. A rational and intriguing hypothesis, to induce differentiation of APL cells rather than killing them, was raised in the 1970s. Laudably, the use of all-trans retinoic acid (ATRA) in treating APL resulted in terminal differentiation of APL cells and a 90-95% CR rate of patients, turning differentiation therapy in cancer treatment from hypothesis to practice. The combination of ATRA with CT further improved the 5-year overall survival. When arsenic trioxide (ATO) was used to treat relapsed APL not only the patients but also the ancient drug were revived. ATO exerts dose-dependent dual effects on APL cells: at low concentration, ATO induces partial differentiation, while at relatively high concentration, it triggers apoptosis. Of note, both ATRA and ATO trigger catabolism of the PML-RAR alpha fusion protein which is the key player in APL leukaernogenesis generated from t(15; 17), targeting the RAR alpha (retinoic acid receptor a) or promyelocytic leukaemia (PML) moieties, respectively. Hence, in treating APL both ATRA and ATO represent paradigms for molecularly targeted therapy. At molecular level, ATRA and ATO synergistically modulate multiple downstream pathways/cascades. Strikingly, a clearance of PML-RARa transcript in an earlier and more thorough manner, and a higher quality remission and survival in newly diagnosed APL are achieved when ATRA is combined with ATO, as compared to either monotherapy, making APL a curable disease. Thus, the story of APL can serve as a model for the development of curative approaches for disease; it suggests that molecularly synergistic targeted therapies are powerful tools in cancer, and dissection of disease pathogenesis or anatomy of the cancer genome is critical in developing molecular target-based therapies.

Exogenous Antigen Upregulation Empowers Antibody Targeted Nanochemotherapy of Leukaemia

Exogenous Antigen Upregulation Empowers Antibody Targeted Nanochemotherapy of Leukemia.

Exogenous CD38 Upregulation Enables High-Efficacy Dually Cascade Targeted Molecular Therapy of Leukemia

The Potential for Clinical Translation of Antibody-Targeted Nanoparticles in the Treatment of Acute Myeloid Leukaemia

Re-Evaluation of Various Molecular Targets Located on Cd34(+)Cd38(-)Lin(-) Leukemia Stem Cells and Other Cell Subsets in Pediatric Acute Myeloid Leukemia

Leukemia Cell Hitchhiking Hypoxia Responsive Nanogel for Improved Immunotherapy of Acute Myeloid Leukemia

Nanomicelles co-loading CXCR4 antagonist and doxorubicin combat the refractory acute myeloid leukemia

All-trans retinoic acid improves NSD2-mediated RARα phase separation and efficacy of anti-CD38 CAR T-cell therapy in multiple myeloma

Upregulation of Cd54 and Downregulation of Hla-Abc Contribute to the Novel Enhancement of the Susceptibility of Hl-60 Cells to Nk Cell-Mediated Cytolysis Induced by Atra Plus Vpa

Abstract 479: Enhanced payload delivery for acute myeloid leukemia treatment through CD37-targeting DNA nanobots

Antibody-Targeted Cyclodextrin-Based Nanoparticles for Sirna Delivery in the Treatment of Acute Myeloid Leukemia: Physicochemical Characteristics, in Vitro Mechanistic Studies, and Ex Vivo Patient Derived Therapeutic Efficacy

Epigenetic targeting to enhance acute myeloid leukemia-directed immunotherapy

Efficient Tumor-Targeting Delivery of Sirna Via Folate-Receptor Mediated Biomimetic Albumin Nanoparticles Enhanced by All-Trans Retinoic Acid

Targeting the redox vulnerability of acute myeloid leukaemia cells with a combination of auranofin and vitamin C

Targeting Epigenetic Pathway with Gold Nanoparticles for Acute Myeloid Leukemia Therapy

Treatment of acute promyelocytic leukaemia with all-trans retinoic acid and arsenic trioxide: a paradigm of synergistic molecular targeting therapy.

All-trans Retinoic Acid Synergizes with Topotecan to Suppress AML Cells Via Promoting RARα-mediated DNA Damage

Adaptive immunity cooperates with liposomal all-trans-retinoic acid (ATRA) to facilitate long-term molecular remissions in mice with acute promyelocytic leukemia

Enhanced T cell activation and cytotoxicity against AML via targeted anti-CD99 nanoparticle treatment

Antibody therapies for the treatment of acute myeloid leukemia: exploring current and emerging therapeutic targets

Treatment of Acute Promyelocytic Leukemia with ATRA and As2O3: a Model of Molecular Target-Based Cancer Therapy.